Emend
aprepitant
Table of contents
Overview
Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting.
Emend is used in patients aged from 6 months to prevent nausea and vomiting caused by chemotherapy (medicines used to treat cancer). It is used with chemotherapy that is a moderate or strong trigger of nausea and vomiting.
Emend contains the active substance aprepitant.
-
List item
Emend : EPAR - Medicine overview (PDF/111.69 KB)
First published: 20/10/2008
Last updated: 17/03/2021
EMA/313469/2020 -
-
List item
Emend : EPAR - Risk Management Plan (PDF/755.05 KB)
First published: 28/04/2023
Authorisation details
Product details | |
---|---|
Name |
Emend
|
Agency product number |
EMEA/H/C/000527
|
Active substance |
Aprepitant
|
International non-proprietary name (INN) or common name |
aprepitant
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
A04AD12
|
Publication details | |
---|---|
Marketing-authorisation holder |
Merck Sharp & Dohme B.V.
|
Revision |
30
|
Date of issue of marketing authorisation valid throughout the European Union |
11/11/2003
|
Contact address |
Waarderweg 39 |
Product information
29/08/2022 Emend - EMEA/H/C/000527 - N/0068
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antiemetics and antinauseants
Therapeutic indication
Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.
Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).
Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.
Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.
Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy.